CEO Total Pay
$15.9M
FY2024 Summary Compensation, well above median
PCRX FY2024 SEC EDGAR DEF 14A
Pacira BioSciences, Inc. CEO pay ratio
The CEO earned $15.9M in FY2024 against median worker pay of $234,476 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2025-04-29
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Pacira BioSciences, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
68:1
Moderate (Scale: 0–1000:1)
CEO pay
$15.9M
Median worker
$234,476
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Pacira BioSciences, Inc. reported a 68:1 CEO-to-worker pay ratio in FY2024 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 68:1
- FY2024 disclosed
- CEO total
- $15.9M
- Summary Compensation Table total
- Median worker
- $234,476
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Pacira BioSciences, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Pacira BioSciences, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 68:1
- FY2024
- vs prior FY
- +33:1
- from FY2023 35:1
- CEO $ YoY
- +132%
- $15.9M latest
- Filings shown
- 4
- FY2021–2024
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $6.9M | - | $198,357 | 35:1 | - |
| 2022 | $6.9M | -1.3% | $195,753 | 35:1 | 0:1 |
| 2023 | $6.9M | +0.4% | $196,517 | 35:1 | 0:1 |
| 2024 | $15.9M | +132% | $234,476 | 68:1 | +33:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1396814, FY2021–2024. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
68:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$15.9M
Companies in Industry
168
vs. Industry Median
Above
Pacira BioSciences, Inc.: MODEST · PEAK pay ratio
Pacira BioSciences, Inc. disclosed 68:1 CEO-to-worker pay and $15.9M CEO total in FY2024. the CEO earned 68× the median employee ($234,476) in FY2024.
Median employee $234,476 (ELITE-MED); MODEST · PEAK stamps put about 68 median-wage years per CEO year.
Pay Ratio
68:1
Near industry median
What FY2024 shows for Pacira BioSciences, Inc.
Pacira BioSciences, Inc. disclosed 68:1 CEO-to-worker pay and $15.9M CEO total in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Pacira BioSciences, Inc.'s $15.9M CEO total is above the $7.9M industry median CEO pay.
Pacira BioSciences, Inc. stamps MODEST · PEAK · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $15.9M
- Median Employee Pay
- $234,476
- Pay Ratio
- 68:1
- Filing Date
- 2025-04-29
Company Info
- Ticker
- PCRX
- CIK
- 1396814
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1396814, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Pacira BioSciences, Inc. disclosed 68:1 CEO-to-worker pay and $15.9M CEO total in FY2024.
Read with Pacira BioSciences, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.
Lincoln National Corp · PEAK
ABS(ceo_total_comp) peer at $15.9M (Δ $41K lighter vs Pacira BioSciences, Inc.); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Stanley Black & Decker, Inc. · PEAK
ABS(ceo_total_comp) peer at $16.0M (Δ $86K heavier vs Pacira BioSciences, Inc.); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Kennedy-Wilson Holdings, Inc. · PEAK
ABS(ceo_total_comp) peer at $15.8M (Δ $102K lighter vs Pacira BioSciences, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
MGM Resorts International · PEAK
ABS(ceo_total_comp) peer at $15.8M (Δ $125K lighter vs Pacira BioSciences, Inc.); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Pacira BioSciences, Inc. stamps MODEST · PEAK · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · PEAK packages sit on the national leaderboard after reading Pacira BioSciences, Inc..
Ratio primer · MODEST
Pacira BioSciences, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Pacira BioSciences, Inc. (CIK 1396814), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.